red.jpg
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
October 08, 2020 10:30 ET | RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
red.jpg
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
August 03, 2020 07:00 ET | RedHill Biopharma Ltd.
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019 --RedHill and Daiichi Sankyo replaced their co-commercialization...
BioDelivery Sciences logo
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
August 28, 2019 07:45 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences logo
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
July 09, 2019 08:00 ET | BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences logo
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
April 10, 2019 16:06 ET | BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC  ...
Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
June 12, 2014 14:41 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today issued the following statement regarding the...
Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
May 06, 2014 06:45 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of...
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
May 01, 2014 06:45 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
March 12, 2014 20:00 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) today announced that Sucampo Pharma Europe, Ltd., its wholly owned subsidiary, has received a...